My post (and this discussion) was about FDA approval and not about the patent case.
The points here are that: - Marine indication were granted by FDA to Amrn on the basis of lowering high TG's. Meanwhile the ability to lower TG's without increasing LDL is good thing it was not a requirement - ANDAs will be approved based on written requirement